Genetron : 2Q21 Presentation

Genetron Holdings Limited

(Nasdaq: GTH) 2Q 2021 Financial Results

August 2021

Disclaimer

The following presentation has been prepared by Genetron Holdings Limited ("Genetron Health" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document contains certain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1953, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company's future financial or business performance, strategies or expectations. These statements typically contain words such as "believe," "may," "will," "could," "expects" and "anticipates" and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement and involves known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. There can be no assurance that the results and events contemplated by the forward looking statements contained herein will in fact occur. None of the future projections, expectations, estimates or

prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations,

estimates or prospects have been prepared are correct or exhaustive or, in the case of assumptions, fully stated in the document. The Company also cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time and which may be beyond the Company's control. The Company assumes no duty to and does not undertake to update any forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting these statements. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission.

This document also contains non-IFRS financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with International Financial Reporting Standards. In addition, the Company's calculation of these non-IFRS financial measures may be different from the calculation used by other companies, and therefore

comparability may be limited. The reconciliation of those measures to the most comparable IFRS measures is contained within this document or available at our website http://ir.genetronhealth.com.

This document speaks as of August 24, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

1

Leading Precision Oncology Company in China

Total

Addressable

Market

			No.1 in China for IVD
	Biopharma	Diagnosis &	approved products
No.1 in China for
Services	Monitoring	Top 3 in China for LDT
Biopharma Partners	TAM $0.5bn	TAM $6.7bn
			Revenue

Market potential in China(1)

~40 Total Biopharma

7 Products in Pipeline

Three

Proprietary

Technology

Platforms

PartnersEarly Screening2-day TAT for S5+Lung 8

$7.2bn liver TAM $5.8bn lung

$23bn CRC	1st Published Liver Cancer
	Prospective Study

One-step Seq

Mutation Capsules

FusionScan

Source: Frost & Sullivan

1. Market potential as of 2023

2

Table of Contents

• Recent Events & Business Updates
• 2Q2021 Financials
• Milestones and Growth Strategy
• Appendix

3

2Q 2021 & Recent Events Recap

Revenue growth with momentum across all business segments

• Total revenue RMB 140.5 million for 2Q2021, 38.1% y/y revenue growth. Gross margin improved to 67.2% vs 63.1% in 2Q2020
• LDT revenue increased by 15.0% yoy to RMB 87.1 million
• IVD revenue increased by 141.5% yoy to RMB 43.8 million
• Development Services revenue increased by 21.8% yoy to RMB 9.5 million

Early-screening business with first-mover advantage

• Registrational trial for HCCscreenTM on track to be initiated
• Case-controlCRC data for early screening expected to be released later this year
• Established collaboration with Guizhou Province's Dafang County to increase access to leading early cancer screening services for high risk liver cancer patients in China's rural markets

Partnership with leading biopharma companies

• Partnered with a leading MNC on Seq-MRD® and expect to launch as LDT service soon
• Solid tumor MRD studies ongoing
• AYVAKIT® companion diagnostic kit, developed in partnership with CStone Pharmaceuticals entered the priority review and approval process under the NMPA in China

Top player in diagnosis business with comprehensive pipeline

• Registrational trial for Onco Panscan on track to be initiated
• Received CE Mark for 8-gene Lung Cancer Assay
• Partnership with Shanghai Yikon Genomics Technology Co., to leverage our S5 instrument platform in reproductive health

4